The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
looks like Covid19 is not effecting Hikma .
Hikma Pharmaceuticals Plc
HIK
2,323.00 GBX
+98.00 (4.40%)
Average volume 699.96k
Shares outstanding 242.33m
Free float 134.67m
P/E (TTM) 13.49
Market cap 5.27bn GBP
EPS (TTM) 1.61 GBP
Hikma Pharmaceuticals Plc 14.8% Potential Upside Indicated by Citigroup
Posted by: Amilia Stone 3rd April 2020
Hikma Pharmaceuticals Plc with EPIC/TICKER (LON:HIK) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Citigroup. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Citigroup have set their target price at 2500 GBX on its stock. This would imply the analyst believes there is now a potential upside of 14.8% from the opening price of 2177 GBX. Over the last 30 and 90 trading days the company share price has increased 248.5 points and increased 242.5 points respectively. The 1 year high for the stock price is 2228.61 GBX while the year low stock price is currently 1553 GBX.
Hikma Pharmaceuticals Plc has a 50 day moving average of 1,911.18 GBX and a 200 Day Moving Average share price is recorded at 1,952.76. There are currently 242,329,031 shares in issue with the average daily volume traded being 805,511. Market capitalisation for LON:HIK is £5,374,857,907 GBP.
it is looking even better today, wow
2,204.00 GBX +146.00 (7.09%)
2 Apr, 08:02 BST · Disclaimer
I hope you topped up mate ,HIK is recovering better than any FTSE 100 Pharma's.
Very good results. Awaiting the next market drop.
BARCLAYS RAISES HIKMA PHARMACEUTICALS PRICE TARGET TO 1950 (1900) PENCE - 'EQUAL WEIGHT'
2019 reported results summary
· Group revenue of $2,207 million, up 7%
· Group operating profit of $493 million, up 33%
· Basic earnings per share of 200.8 cents, up 72%
· Cashflow from operating activities of $472 million, up 10%
· Net debt reduced to $242 million and low leverage maintained (net debt to core EBITDA2 ratio 0.4x)
· Full year dividend of 44 cents per share, up from 38 cents per share
They used two
I note you have spelt benefiting wrongly it only has one t.
Quite perverse market reaction to a positive trading statement. It’s almost like saying we resent success.
Fair enough, in the statement they did misspell ‘benefitting’ but it didn’t deserve this.
Maybe it should be described as a technical correction before heading skyward.
is looking very strong today , nice
Cup and handle in play here
Generally, in an uptrend, before a significant upwards movement there is a drop (buying opportunity). It isn’t a nice experience but it goes with the territory.
ditto
"back in to FTSE 100, nice"
3% drop this morning, not so nice!
Any connection?
back in to FTSE 100, nice
one of the better pharmaceuticals this year, looks like they overcome the last years problems. from £8 to £20 not bad in a year.
Good positive RNS today, SP rising :)
The US are moving towards prescription drugs system. What a game changer that would be for generic drugs manufacturers?
Thanks for your feedback Fantom. Yes I to believe this company is going places.
I follow chart patterns and firmly believe this company has a bright future. However, for the charts to be credible, you have to allow them to play themselves out. Positive trading statements aren’t always going to sit well with those who control this share’s price movement. Hence the recent increase by shorting hedge funds.
Anyone any ideas on why the sudden decline? I havnt seen any bad news 're Hik?
FTSE100 drop out would be a good opportunity to load up on shares 🙂
HIK is on the cusp of dropping out of the FTSE , next week, needs to get that mcap up or hope a couple of others around it at the bottom do worse over the coming days.
G